US008062906B2 (12) United States Patent (10) Patent No.: US 8,062.906 B2 Beltzer et al. (45) Date of Patent: *Nov. 22, 2011 (54) B-LYMPHOCYTESTIMULATOR BINDING 6,689,579 B1 2/2004 Yu et al. POLYPEPTIDES AND METHODS BASED SR R $38: E. est al. THEREON 6,812,327 B1 1 1/2004 Yu 6,846,476 B2 1, 2005 White (75) Inventors: James P. Beltzer, Carlisle, MA (US); M. 6,869,605 B2 3/2005 Browning et al. Daniel Potter, Acton, MA (US); Tony J. 6,875,846 B2 4/2005 Rennert et al. Fleming, Waltham, MA (US) 6,881.401 B1 4/2005 Yu 7,083,785 B2 8/2006 Browning et al. (73) Assignee: Human Genome Sciences, Inc., 2. R: 1939: Ea. Rockville, MD (US) 7,220,840 B2 5/2007 Ruben et al. 7,259,137 B2 8, 2007 Minet al. (*) Notice: Subject to any disclaimer, the term of this 7,317,089 B2 1/2008 Kikly patent is extended or adjusted under 35 78.8 R 3. E. s al U.S.C. 154(b) by 0 days. 2001/0010925W-1 r. A1 8/2001 WileyeIIrey et al. This patent is Subject to a terminal dis- 2002fOO37852 A1 3, 2002 Browning et al. claimer 2002/0055624 A1 5/2002 Wiley 2002fO115112 A1 8, 2002 Yu et al. 2002/0150579 A1 10/2002 Kimberly et al. (21) Appl. No.: 12/701,301 2002/0165156 Al 1 1/2002 Browning et al. 2002/0172674 A1 1 1/2002 Jeffrey et al. (22) Filed: Feb. 5, 2010 2003, OO12783 A1 1/2003 Kindsvogel (Continued) (65) Prior Publication Data US 2010/014.4058 A1 Jun. 10, 2010 FOREIGN PATENT DOCUMENTS EP O 439 095 A2 7, 1991 Related U.S. Application Data (Continued) (63) Continuation of application No. 1 1/232,439, filed on OTHER PUBLICATIONS ofSep. application 20, 2005, No.now 09/932,613, abandoned. filedWhich on is Aug. a continuation 17, 2001, GrossU.S. Appl. et al. No. 08/984,396, Hurleet al. U.S. Appl. No. 09/226,533, now abandoned. U.S. Appl. No. 09/589.288, Yu et al. (60) Eyal application No. 60/226,700, filed on Aug. U.S. Appl. No. 09/912,293,12/170,333, YuRosen et al. et al. s U.S. Appl. No. 60/033,601, Gorman. U.S. Appl. No. 60/041,797, Hurle et al. (51) Int. Cl. U.S. Appl. No. 60/048,776, Masiakowsky et al. GOIN33/566 (2006.01) U.S. Appl. No. 60/058,786, Tschopp. A6 IK38/00 (2006.01) U.S. Appl. No. 60/066,386, Masiakowsky et al. (52) U.S. Cl. ........................................ 436/501; 530/326 U.S. Appl. No. 60/066,577, Song. (58) Field of Classification Search ........................ None (Continued) See application file for complete search history. Primary Examiner — Patricia A Duffy (56) References Cited (74) Attorney, Agent, or Firm — Leydig, Voit & Mayer, Ltd. U.S. PATENT DOCUMENTS (57) ABSTRACT 4,179,337 A 12/1979 Davis et al. Binding polypeptides that specifically bind B lymphocyte 5,223,409 A 6, 1993 Ladner et al. stimulator protein or B lymphocyte stimulator-like polypep 5,281,704 A 1/1994 Love tides can be used in methods of the invention for detecting, 5,403.484 A 4/1995 Ladner et al. diagnosing, or prognosing a disease or disorder associated 5,474,981 A 12/1995 Leder et al. with aberrant B lymphocyte stimulator or B lymphocyte 5,571,698 A 11/1996 Ladner et al. 5,576, 195 A 11/1996 Robinson et al. stimulator receptor expression or inappropriate function of B 5,595,721 A 1/1997 Kasminski et al. lymphocyte stimulator or B lymphocyte stimulator receptor, 5,605,671 A 2/1997 Lyle comprising B lymphocyte stimulator binding polypeptides or 5,635,384 A 6, 1997 Walsh et al. fragments or variants thereof, that specifically bind to B lym 5,643,575 A 7, 1997 Martinez et al. 5,795,724. A 8, 1998 Hillman et al. phocyte stimulator. The present invention further relates to 5,846,818 A 12/1998 Robinson et al. methods and compositions for preventing, treating or amelio 5,869,331 A 2/1999 Dornburg rating a disease or disorder associated with aberrant B lym 5.948,619 A 9, 1999 Bandman et al. phocyte stimulator or B lymphocyte stimulator receptor 5,962,301 A 10, 1999 Horvitz et al. expression or inappropriate B lymphocyte stimulator func 5,969,102 A 10, 1999 Bram et al. 6,207,160 B1 3, 2001 Victoria et al. tion or B lymphocyte stimulator receptor function, compris 6,297,367 B1 10/2001 Tribouley ing administering to an animal, preferably a human, an effec 6,403,770 B1 6, 2002 Yu tive amount of one or more B lymphocyte stimulator binding 6,475,987 B1 1 1/2002 Shu polypeptides or fragments or variants thereof, that specifi 6,541,224 B2 4, 2003 Yu cally bind to B lymphocyte stimulator. 6,562,579 B1 5, 2003 Yu et al. 6,635,482 B1 10/2003 Yu et al. 27 Claims, No Drawings US 8,062.906 B2 Page 2 U.S. PATENT DOCUMENTS WO WOOO26244 A2 5, 2000 2003/0022233 A1 1/2003 Goodwin W. W. 828. A. 22999 2003, OO23038 A1 1/2003 Rennert et al. WO WOOOf 43032 A2 T 2000 2003/009 1565 A1 5, 2003 Beltzer et al. WO WOOOf 45836 A1 8, 2000 2003/0095967 A1 5/2003 MacKay et al. WO WOOOf 47740 A2 8, 2000 2003/0148445 A1 8, 2003 Shu WO WOOOf 50597 A2 8, 2000 2003. O166546 A1 9/2003 Aggarwal WO WOOO,58362 A1 10, 2000 2003/01752O8 A1 9, 2003 Yu et al. WO WOOOf 60079 A2 10, 2000 2003/0194743 A1 10, 2003 Beltzer et al. WO WOOO67034 A1 11, 2000 2003,0223996 A1 12, 2003 Ruben et al. WO WOOOf 68378 A1 11, 2000 2004/01758O1 A1 9, 2004 Yu et al. WO WOOOf77256 A1 12/2000 2004/01758O2 A1 9, 2004 Yu et al. WO WO 01/12812 A2 2, 2001 2005/0070694 A1 3/2005 Gelfanova et al. WO WOO1,24811 A1 4/2001 2005, 0100548 A1 5/2005 Browning et al. WO WOO1/40466 A2 6, 2001 2005, 0169924 A1 8/2005 Browning et al. WO WOO1,603.97 A1 8, 2001 2005, 0186637 A1 8, 2005 Yu et al. WO WOO1,81417 A2 11/2001 2005/0214543 A1 9/2005 Koumura et al. WO WOO1,87977 A2 11/2001 2005/0244411 A1 1 1/2005 MacKay et al. WO WO O2/O2641 A1 1, 2002 2005/0255532 A1 11, 2005 Ruben et al. WO WO O2, 16411 A2 2, 2002 2006, OO62789 A1 3, 2006 Ruben et al. WO WO O2, 18620 A2 3, 2002 2006/00794.57 A1 4/2006 Browning et al. WO WO O2/24909 A2 3, 2002 2006, OO84608 A1 4/2006 Beltzer et al. WO WOO2.38766 A2 5, 2002 2006/0171919 A1 8, 2006 Rosenblum et al. WO WO 02/066516 A3 8, 2002 2006, O193859 A1 8, 2006 Yu et al. WO WO O2/O92620 A2 11/2002 2007/0O86979 A1 4/2007 Chevrier et al. WO WO 03/O16468 A2 2, 2003 2007,0293434 A9 12, 2007 Beltzer et al. WO WOO3,O3O833 A2 4/2003 2008/0254030 A1 10/2008 Mackay et al. WO WOO3/033658 A2 4/2003 2008/0267965 A1 10, 2008 Kalled et al. WO WOO3,055979 A2 T 2003 2009,0081213 A1 3/2009 Chevrier et al. WO WOO3,089569 A2 10, 2003 2009/00981.29 A1 4/2009 Farrow et al. WO WO 04/0583.09 A1 T 2004 2009/0110676 A1 4/2009 Mackay et al. WO WO 2004/07451 1 A1 9, 2004 2009/0148462 A1 6/2009 Chevrier et al. WO WO 2005.005462 A3 1/2005 2009, 0215071 A1 8/2009 Cachero et al. WO WO 2005/042009 A1 5, 2005 2010, 004.0627 A1 2/2010 Jeffrey et al. 2010/0233179 A1 9/2010 Browning et al. OTHER PUBLICATIONS . Appl. No. 60/068.959, Tribouley et al. FOREIGN PATENT DOCUMENTS . Appl. No. 60/096, 173, Song. EP O 869 180 A1 10, 1998 . Appl. No. 60/106,976, Lenardo et al. EP O921 194 A1 6, 1999 . Appl. No. 60/117,169, McKay et al. EP 1157 11.0 A1 11, 2001 . Appl. No. 60/119,906, Boyle et al. EP 1294 769 A2 3, 2003 . Appl. No. 60/132,892, Shu. EP 1294 949 A2 3, 2003 EP 1309 718 A2 5, 2003 . Appl. No. 60/143,228, MacKay et al. EP 1 146 892 B1 8, 2003 . Appl. No. 60/149,378, MacKay et al. EP 1 141274 B1 9, 2003 . Appl. No. 60/157,933, Schneider et al. EP 1354 598 A3 10, 2003 . Appl. No. 60/166,271, Boyle et al. EP 1456,347 A2 9, 2004 . Appl. No. 60/201,012, Shu. EP 1507 793 A1 2, 2005 . Appl. No. 60/204,039, Theill. EP 1577 391 A1 9, 2005 . Appl. No. 60/214,591, Theill. EP 1860 190 A2 11, 2007 WO WO93,21232 A1 10, 1993 .S. Appl. No. 60/312,808, Gelfanova. WO WO94/20540 A1 9, 1994 GB, 98.28628.9, Glaxo Group Ltd. WO WO95/07297 A1 3, 1995 Biogen IDEC's opposition of EP Patent No. 1 141 274 B1. Filed in WO WO95/2O398 A1 8, 1995 the European Patent Office on Jun. 10, 2004. WO WO95/24414 A1 9, 1995 Biogen Inc. and Apoxis SA’s Response (including Annexes A and B WO WO95/24466 A1 9, 1995 and the Main Request containing a Substitute set of claims) to Human WO WO95/31468 A1 11, 1995 WO WO 96/14328 A1 5, 1996 Genome Sciences and Serono's Oppositions of EP Patent No.